494 related articles for article (PubMed ID: 1941528)
1. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males.
Baum MK; Javier JJ; Mantero-Atienza E; Beach RS; Fletcher MA; Sauberlich HE; Feaster D; Shor-Posner G
J Acquir Immune Defic Syndr (1988); 1991; 4(12):1218-26. PubMed ID: 1941528
[TBL] [Abstract][Full Text] [Related]
2. Micronutrients and HIV-1 disease progression.
Baum MK; Shor-Posner G; Lu Y; Rosner B; Sauberlich HE; Fletcher MA; Szapocznik J; Eisdorfer C; Buring JE; Hennekens CH
AIDS; 1995 Sep; 9(9):1051-6. PubMed ID: 8527077
[TBL] [Abstract][Full Text] [Related]
3. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
[TBL] [Abstract][Full Text] [Related]
4. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
5. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.
Stretcher BN; Pesce AJ; Frame PT; Greenberg KA; Stein DS
AIDS; 1994 Jun; 8(6):763-9. PubMed ID: 8086134
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two dosing regimens of zidovudine in Thai adults with early symptomatic HIV infection. Conducting clinical HIV trials in South-East Asia.
Phanuphak P; Grayson ML; Sirivichayakul S; Suwanagool S; Ruxrungtham K; Hanvanich M; Ratanasuwan W; Ubolyam S; Hughes MD; Wanke CA; Hammer SM
Aust N Z J Med; 2000 Feb; 30(1):11-20. PubMed ID: 10800872
[TBL] [Abstract][Full Text] [Related]
7. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
[TBL] [Abstract][Full Text] [Related]
8. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results in HIV-1-infected patients treated with transfer factor (TF) and zidovudine (ZDV).
Raise E; Guerra L; Viza D; Pizza G; De Vinci C; Schiattone ML; Rocaccio L; Cicognani M; Gritti F
Biotherapy; 1996; 9(1-3):49-54. PubMed ID: 8993757
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study.
Meng TC; Fischl MA; Cheeseman SH; Spector SA; Resnick L; Boota A; Petrakis T; Wright B; Richman DD
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Feb; 8(2):152-60. PubMed ID: 7834398
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
Burger DM; Meenhorst PL; ten Napel CH; Mulder JW; Neef C; Koks CH; Bult A; Beijnen JH
AIDS; 1994 Dec; 8(12):1683-9. PubMed ID: 7888117
[TBL] [Abstract][Full Text] [Related]
13. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.
Zazzi M; Catucci M; De Milito A; Romano L; Venturi G; Almi P; Gonnelli A; Rubino M; Valensin PE
Infection; 1996; 24(6):419-25. PubMed ID: 9007588
[TBL] [Abstract][Full Text] [Related]
15. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
16. Anemia among HIV Infected Individuals Taking ART with and without Zidovudine at Addis Ababa, Ethiopia.
Tamir Z; Alemu J; Tsegaye A
Ethiop J Health Sci; 2018 Jan; 28(1):73-82. PubMed ID: 29622909
[TBL] [Abstract][Full Text] [Related]
17. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Moolasart P; Likanonsakul S
Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
[TBL] [Abstract][Full Text] [Related]
19. Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudine.
Baroncelli S; Pinnetti C; Genovese O; Tamburrini E; Floridia M
J Med Virol; 2011 Mar; 83(3):551-6. PubMed ID: 21264878
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
Wintermeyer SM; Nahata MC; Brady MT; Sobol BJ; Venglarcik JS 3rd ; Baker RC; Hunkler JA; McOwen NM
Pediatr AIDS HIV Infect; 1997 Apr; 8(2):120-6. PubMed ID: 11361778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
